SCHEMBL1704464

SCHEMBL1704464

C[C@@H]1CN(Cc2ccc(C(C)(C)C(=O)N3CCC(Nc4cccc(F)c4)CC3)cc2)C[C@H](C)N1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
MLNR O43193 20/20 1.00
CYP3A4 P08684 8/20 0.81
CYP2D6 P10635 2/20 0.64
CYP1A2 P05177 1/20 0.64
GHSR Q92847 1/20 0.64
KCNH2 Q12809 1/20 0.63

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4597664 0.90 MLNR (0.82) MLNRCYP3A4CYP2D6CYP1A2GHSR
SCHEMBL1704589 0.89 MLNR (1.00) MLNRCYP3A4CYP2D6CYP1A2GHSR
SCHEMBL1704176 0.84 MLNR (1.00) MLNRCYP3A4CYP2D6CYP1A2GHSR
SCHEMBL1704769 0.84 MLNR (1.00) MLNRCYP3A4CYP2D6CYP1A2GHSR
SCHEMBL377500 0.83 MLNR (0.73) MLNRCYP3A4CYP2D6CYP1A2GHSR
SCHEMBL13928035 0.80 MLNR (0.70) MLNRCYP3A4CYP2D6GHSR
SCHEMBL14618440 0.79 MLNR (0.80) MLNRCYP3A4CYP2D6CYP1A2GHSR
SCHEMBL5127680 0.78 MLNR (1.00) MLNRCYP3A4CYP2D6CYP1A2GHSR
SCHEMBL4787915 0.78 MLNR (1.00) MLNRCYP3A4CYP2D6CYP1A2GHSR
SCHEMBL5131588 0.78 MLNR (1.00) MLNRCYP3A4CYP2D6CYP1A2GHSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130317041-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-11-28 US claimed
EP-1907374-B1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders GLAXO GROUP LTD (GB) 2012-08-22 EP claimed
EP-2441763-A1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders Glaxo Group Limited (GB) 2012-04-18 EP claimed
US-20090054456-A1 BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE GLAXO GROUP LIMITED (GB) 2009-02-26 US claimed
EP-1907374-A2 COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-04-09 EP claimed
WO-2007012479-A2 BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE GLAXO GROUP LIMITED (GB) 2007-02-01 WO claimed
US-20130317041-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-11-28 US disclosed
US-8536182-B2 Benzylpiperazine derivatives and their medical use GLAXO GROUP LIMITED (GB) 2013-09-17 US disclosed
EP-1907374-B1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders GLAXO GROUP LTD (GB) 2012-08-22 EP disclosed
EP-2441763-A1 Benzylpiperazine derivatives useful for the treatment of gastrointestinal disorders Glaxo Group Limited (GB) 2012-04-18 EP disclosed
US-20090054456-A1 BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE GLAXO GROUP LIMITED (GB) 2009-02-26 US disclosed
EP-1907374-A2 COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-04-09 EP disclosed
WO-2007012479-A2 BENZYLPIPERAZINE DERIVATES AND THEIR MEDICAL USE GLAXO GROUP LIMITED (GB) 2007-02-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054456-A1 BENZYLPIPERAZINE DERIVATIVES AND THEIR MEDICAL USE GPR68, GPR88, GPR55 MLNR 87/4885CYP3A4 606/4885CYP2D6 582/4885
US-20130317041-A1 COMPOUNDS GPR68, GPR88, GPR35 MLNR 71/4885CYP3A4 647/4885CYP2D6 787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.